Priority 8 from the Mesothelioma PSP

UNCERTAINTY: In mesothelioma, is there a role for intrapleural immunostimulants (drugs designed to stimulate an anti-cancer immune response, such as corynebacterium parvum extract) in addition to any other treatment? (JLA PSP Priority 8)
Overall ranking 8
JLA question ID 0025/8 
Explanatory note Not available for this PSP
Evidence No systematic reviews identified.  Ongoing study - A Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy.
Health Research Classification System category Cancer
Extra information provided by this PSP
Original uncertainty examples Much more research into immunotherapy and cancer cell DNA is required ~ Can the immune system be stimulated to fight mesothelioma?
Comparison None identified
Submitted by Patient x 2
Outcomes to be measured Survival
PSP information
PSP unique ID 0025
PSP name Mesothelioma
Total number of uncertainties identified by this PSP. 53  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 16 December 2014